Modern approaches to the diagnosis, treatment and prevention of obesity

Abstract

Approximately 2 billion people worldwide are overweight, including about 20% of adults and a quarter of a billion children. In Russia and Europe, about 60% of the population is diagnosed with obesity. According to global data, obesity is the fifth leading risk factor for premature death. The World Health Organization predicts that the number of people with morbid obesity will nearly double in the near future. Obesity increases the risk of cardiovascular, endocrine, and digestive diseases, obstructive sleep apnea, osteoarthritis, etc. Socio-demographic, behavioral and genetic factors are common causes of obesity. The diagnosis of obesity is made through the integrated use of parameters such as body mass index, waist circumference, fasting triglyceride levels, and others. Radiographic and ultrasound methods are being actively implemented. Today in Russia the choice of drugs for the treatment of obesity is very limited. Orlistat, sibutramine, liraglutide are approved for this indication. In addition, gastric electrostimulation and various surgical methods of treatment are effectively used. A targeted and comprehensive approach to improving the healthcare system for people with overweight and obesity should be a key factor in achieving the national goal of improving people’s health and well-being. Escalation of prevention efforts at all levels will help significantly reduce the spread of this disease and prevent its development around the world.

Keywords

overweight / obesity / body mass index

References

[1] Dzhioeva ON, Angarsky RK, Shvartz EN, et al. Visceral obesity: key risk factors and diagnostic aspects (review). Saratov Journal of Medical Scientific Research. 2022;18(2):234–239. EDN: OARXQB

[2] Джиоева О.Н., Ангарский Р.К., Шварц Е.Н., и др. Висцеральное ожирение: ключевые факторы риска и аспекты диагностики (обзор) // Саратовский научно-медицинский журнал. 2022. Т. 18, № 2. С. 234–239. EDN: OARXQB

[3] Lyasnikova MB, Belyakova NA, Tsvetkova IG, et al. Risk of developing severe alimentary-constitutional obesity and metabolic disorders: interventional comparative study. Kuban Scientific Medical Bulletin. 2023;30(1):49–57. EDN: NSELMH doi: 10.25207/1608-6228-2023-30-1-49-57

[4] Лясникова М.Б., Белякова Н.А., Цветкова И.Г., и др. Риски развития выраженного алиментарно-конституционального ожирения и метаболических нарушений: интервенционное сравнительное исследование // Кубанский научный медицинский вестник. 2023. Т. 30, № 1. С. 49–57. EDN: NSELMH doi: 10.25207/1608-6228-2023-30-1-49-57

[5] Vasyukova OV, Okorokov PL, Kasyanova YuV, Bezlepkina OB. Energy exchange: how we can personalize obesity therapy. Problems of Endocrinology. 2021;67(5):4–10. EDN: PBCCRU doi: 10.14341/probl12830

[6] Васюкова О.В., Окороков П.Л., Касьянова Ю.В., Безлепкина О.Б. Энергетический обмен человека: как мы можем персонифицировать терапию ожирения // Проблемы эндокринологии. 2021. Т. 67, № 5. С. 4–10. EDN: PBCCRU doi: 10.14341/probl12830

[7] Kim OT, Drapkina OM. Obesity epidemic through the prism of evolutionary processes. Cardiovascular Therapy and Prevention. 2022;21(1):72–79. EDN: MUTNZI doi: 10.15829/1728-8800-2022-3109

[8] Ким О.Т., Драпкина О.М. Эпидемия ожирения через призму эволюционных процессов // Кардиоваскулярная терапия и профилактика. 2022. Т. 21, № 1. С. 72–79. EDN: MUTNZI doi: 10.15829/1728-8800-2022-3109

[9] Seidell JC. Obesity: a growing problem. Acta Paediatr Suppl. 1999;88(428):46–50. doi: 10.1111/j.1651-2227.1999.tb14350.x

[10] Seidell J.C. Obesity: a growing problem // Acta Paediatr Suppl. 1999. Vol. 88, N 428. P. 46–50. doi: 10.1111/j.1651-2227.1999.tb14350.x

[11] Kumanyika S, Dietz WH. Solving population-wide obesity — progress and future prospects. N Engl J Med. 2020;383(23): 2197–2200. doi: 10.1056/NEJMp2029646

[12] Kumanyika S., Dietz W.H. Solving population-wide obesity — progress and future prospects // N Engl J Med. 2020. Vol. 383, N 23. P. 2197–2200. doi: 10.1056/NEJMp2029646

[13] Chubarov TV, Bessonova AV, Zhdanova OA, et al. Risk factors for obesity development in different periods of childhood. Obesity and Metabolism. 2021;18(2):163–168. EDN: HEPAWF doi: 10.14341/omet12756

[14] Чубаров Т.В., Бессонова А.В., Жданова О.А., и др. Факторы риска развития ожирения в различные периоды детства // Ожирение и метаболизм. 2021. Т. 18, № 2. С. 163–168. EDN: HEPAWF doi: 10.14341/omet12756

[15] Peterkova VA, Bezlepkina OB, Bolotova NV, et al. Clinical guidelines "Obesity in children". Problems of Endocrinology. 2021;67(5):67–83. EDN: IXIZSV doi: 10.14341/probl12802

[16] Петеркова В.А., Безлепкина О.Б., Болотова Н.В., и др. Клинические рекомендации «Ожирение у детей» // Проблемы эндокринологии. 2021. Т. 67, № 5. С. 67–83. EDN: IXIZSV doi: 10.14341/probl12802

[17] Chubarov TV, Zhdanova OA, Sharshova OG, et al. Artificial intelligence predicting the risk of obesity in children. Aspirantskiy Vestnik Povolzhiya. 2022;22(1):64–70. EDN: AUKYRS doi: 10.55531/2072-2354.2022.22.1.64-70

[18] Чубаров Т.В., Жданова О.А., Шаршова О.Г., и др. Искусственный интеллект в прогнозировании степени риска развития ожирения у детей // Аспирантский вестник Поволжья. 2022. Т. 22, № 1. С. 64–70. EDN: AUKYRS doi: 10.55531/2072-2354.2022.22.1.64-70

[19] Berry EM. The obesity pandemic — whose responsibility? No blame, no shame, not more of the same. Front Nutr. 2020;7:2. doi: 10.3389/fnut.2020.00002

[20] Berry E.M. The obesity pandemic — whose responsibility? No blame, no shame, not more of the same // Front Nutr. 2020. Vol. 7. P. 2. doi: 10.3389/fnut.2020.00002

[21] Zabolotskikh IB, Anisimov MA, Gorobets ES, et al. Perioperative management of patients with concomitant morbid obesity. Guidelines of the all-Russian public organization "Federation of Anesthesiologists and Reanimatologists". Annals of Critical Care. 2021;(1):7–18. EDN: YHJNQH doi: 10.21320/1818-474X-2021-1-7-18

[22] Заболотских И.Б., Анисимов М.А., Горобец Е.С., и др. Периоперационное ведение пациентов с сопутствующим морбидным ожирением. Методические рекомендации Общероссийской общественной организации «Федерация анестезиологов и реаниматологов» // Вестник интенсивной терапии имени А.И. Салтанова. 2021. № 1. С. 7–18. EDN: YHJNQH doi: 10.21320/1818-474X-2021-1-7-18

[23] Antonopoulos AS, Tousoulis D. The molecular mechanisms of obesity paradox. Cardiovasc Res. 2017;113(9):1074–1086. doi: 10.1093/cvr/cvx106

[24] Antonopoulos A.S., Tousoulis D. The molecular mechanisms of obesity paradox // Cardiovasc Res. 2017. Vol. 113, N 9. P. 1074–1086. doi: 10.1093/cvr/cvx106

[25] German AI, Sedykh DYu, Hryachkova ON, Kashtalap VV. Abdominal obesity and ten-year prognosis of patients with myocardial infarction. Complex Issues of Cardiovascular Diseases. 2021;10(1):26–39. EDN: QETIIU doi: 10.17802/2306-1278-2021-10-1-26-39

[26] Герман А.И., Седых Д.Ю., Хрячкова О.Н., Кашталап В.В. Абдоминальное ожирение и 10-летний прогноз пациентов с инфарктом миокарда // Комплексные проблемы сердечно-сосудистых заболеваний. 2021. Т. 10, № 1. С. 26–39. EDN: QETIIU doi: 10.17802/2306-1278-2021-10-1-26-39

[27] Panova EI, Pimankina MS. Coronavirus infection an obese patient (literature review). The Russian Archives of Internal Medicine. 2021;11(3):209–216. EDN: ICNGAH doi: 10.20514/2226-6704-2021-11-3-209-216

[28] Панова Е.И., Пиманкина М.С. Коронавирусная инфекция у пациента с ожирением (обзор литературы) // Архивъ внутренней медицины. 2021. Т. 11, № 3. С. 209–216. EDN: ICNGAH doi: 10.20514/2226-6704-2021-11-3-209-216

[29] Chen ZA, Roy K, Gotway Crawford CA. Obesity prevention: the impact of local health departments. Health Serv Res. 2013;48(2 Pt 1):603–627. doi: 10.1111/j.1475-6773.2012.01447.x

[30] Chen Z.A., Roy K., Gotway Crawford C.A. Obesity prevention: the impact of local health departments // Health Serv Res. 2013. Vol. 48, N 2, Pt 1. P. 603–627. doi: 10.1111/j.1475-6773.2012.01447.x

[31] Lerman OV, Lukina YuV, Kutishenko NP, et al. The problem of obesity "through the eyes" of patients (results of the survey of patients of the outpatient registry). Rational Pharmacotherapy in Cardiology. 2022;18(5):578–584. EDN: NDFFKI doi: 10.20996/1819-6446-2022-10-05

[32] Лерман О.В., Лукина Ю.В., Кутишенко Н.П., и др. Проблема ожирения глазами пациентов (по результатам анкетирования больных амбулаторного регистра) // Рациональная фармакотерапия в кардиологии. 2022. Т. 18, № 5. С. 578–584. EDN: NDFFKI doi: 10.20996/1819-6446-2022-10-05

[33] Egorova VV, Brumberg AA. A dependence of the obesity prevalence on the consumption structure for the main food groups in the population of the Russian Federation and the city of Moscow. City-Healthcare. 2021;2(4):6–15. EDN: TOLZGU

[34] Егорова В.В., Брумберг А.А. Зависимость распространенности ожирения от структуры потребления основных групп продуктов питания населения Российской Федерации и города Москвы // Здоровье мегаполиса. 2021. Т. 2, № 4. С. 6–15. EDN: TOLZGU

[35] Chumakova GA, Veselovskaya NG, Kozarenko AA, Vorobyeva YuV. Heart morphology, structure, and function in obesity. Russian Journal of Cardiology. 2012;17(4):93–99. EDN: PBUQHP

[36] Чумакова Г.А., Веселовская Н.Г., Козаренко А.А., Воробьева Ю.В. Особенности морфологии, структуры и функции сердца при ожирении // Российский кардиологический журнал. 2012. Т. 17, № 4. С. 93–99. EDN: PBUQHP

[37] Nimptsch K, Konigorski S, Pischon T. Diagnosis of obesity and use of obesity biomarkers in science and clinical medicine. Metabolism. 2019;92:61–70. doi: 10.1016/j.metabol.2018.12.006

[38] Nimptsch K., Konigorski S., Pischon T. Diagnosis of obesity and use of obesity biomarkers in science and clinical medicine // Metabolism. 2019. Vol. 92. P. 61–70. doi: 10.1016/j.metabol.2018.12.006

[39] Druzhilov MA, Kuznetsova TYu. Epicardial adiposity as a predictor of covid-19 severity in overweight and obese patients. Russian Journal of Cardiology. 2022;27(3):39–44. EDN: PLXCBG doi: 10.15829/1560-4071-2022-4850

[40] Дружилов М.А., Кузнецова Т.Ю. Эпикардиальное висцеральное ожирение как предиктор тяжести течения Covid-19 у пациентов с избыточным весом и ожирением // Российский кардиологический журнал. 2022. Т. 27, № 3. С. 39–44. EDN: PLXCBG doi: 10.15829/1560-4071-2022-4850

[41] Syurin SA, Gorbanev SA. Prevalence and correlates of obesity in industrial workers in Arctic Russia. Ecologiya cheloveka (Human Ecology). 2021;28(5):28–35. EDN: UCSYJM doi: 10.33396/1728-0869-2021-5-28-35

[42] Сюрин С.А., Горбанев С.А. Ожирение как фактор риска здоровью работников предприятий в Российской Арктике // Экология человека. 2021. Т. 28, № 5. С. 28–35. EDN: UCSYJM doi: 10.33396/1728-0869-2021-5-28-35

[43] Salekhova MP, Gulov MK, Abdulloev SM, Korabelnikov AI. Pathogenetic significance of psychological stress in the development of alimentary obesity. Vestnik NovSU. Issue: Medical Sciences. 2021;(1):58–61. EDN: CWMVPU doi: 10.34680/2076-8052.2021.1(122).58-61

[44] Салехова М.П., Гулов М.К., Абдуллоев С.М., Корабельников А.И. Психологический стресс как патогенетический триггер развития алиментарного ожирения // Вестник Новгородского государственного университета. 2021. № 1. С. 58–61. EDN: CWMVPU doi: 10.34680/2076-8052.2021.1(122).58-61

[45] Ismael U, Khafagy W, El Bassioune W, et al. Explicating the negative impact of obesity on the quality of life in older women with stress urinary incontinence. Gynecology, Obstetrics and Perinatology. 2022;21(4):60–68.

[46] Ismael U., Khafagy W., El Bassioune W., et al. Explicating the negative impact of obesity on the quality of life in older women with stress urinary incontinence // Gynecology, Obstetrics and Perinatology. 2022. Vol. 21, N 4. P. 60–68.

[47] Khamoshina MB, Artemenko YuS, Bayramova AA, et al. Polycystic ovary syndrome and obesity: a modern paradigm. RUDN Journal of Medicine. 2022;26(4):382–395. EDN: HVMYRO doi: 10.22363/2313-0245-2022-26-4-382-395

[48] Хамошина М.Б., Артеменко Ю.С., Байрамова А.А., и др. Синдром поликистозных яичников и ожирение: современная парадигма // RUDN Journal of Medicine. 2022. Т. 26, № 4. С. 382–395. EDN: HVMYRO doi: 10.22363/2313-0245-2022-26-4-382-395

[49] Mamatov A, Polupanov A, Kakeev B, et al. Physical inactivity and low educational level as factors associated with the development of obesity. The Scientific Heritage. 2021;(68-2):39–46. EDN: BXUCQK doi: 10.24412/9215-0365-2021-68-2-39-46

[50] Маматов А.У., Полупанов А.Г., Какеев Б.А., и др. Гиподинамия и низкий уровень образования, как факторы, ассоциированные с развитием ожирения // The Scientific Heritage. 2021. № 68-2. С. 39–46. EDN: BXUCQK doi: 10.24412/9215-0365-2021-68-2-39-46

[51] Berkovskaya MA, Gurova OY, Khaykina IA, Fadeev VV. Time-restricted eating as a novel strategy for treatment of obesity and it’s comorbid conditions. Problems of Endocrinology. 2022;68(4):78–91. EDN: FOUMEQ doi: 10.14341/probl13078

[52] Берковская М.А., Гурова О.Ю., Хайкина И.А., Фадеев В.В. Питание, ограниченное по времени, как новая стратегия терапии ожирения и коморбидных состояний // Проблемы эндокринологии. 2022. Т. 68, № 4. С. 78–91. EDN: FOUMEQ doi: 10.14341/probl13078

[53] Tkachenko V, Bagro T. Quality of life, mental health and sleep disorders in obese people of working age. West Kazakhstan Medical Journal. 2021;(3):145–151. EDN: UVMJKY doi: 10.24412/2707-6180-2021-63-145-151

[54] Ткаченко В., Багро Т. Качество жизни, психическое здоровье и нарушения сна у людей трудоспособного возраста с ожирением // West Kazakhstan Medical Journal. 2021. № 3. С. 145–151. EDN: UVMJKY doi: 10.24412/2707-6180-2021-63-145-151

[55] Medanić D, Pucarin-Cvetković J. Obesity — a public health problem and challenge. Acta Med Croatica. 2012;66(5):347–355. (In Croatian).

[56] Medanić D., Pucarin-Cvetković J. Pretilost — javnozdravstveni problem iizazov // Acta Med Croatica. 2012. Vol. 66, N 5. P. 347–355.

[57] Tikhonov SV, Bakulina NV, Simanenkov VI. Overweight and obese patients on gastroenterological visit. Medical Alphabet. 2022;(12):7–11. EDN: KNJQVO doi: 10.33667/2078-5631-2022-12-7-11

[58] Тихонов С.В., Бакулина Н.В., Симаненков В.И. Пациенты с избыточным весом и ожирением на приеме у гастроэнтеролога // Медицинский алфавит. 2022. № 12. С. 7–11. EDN: KNJQVO doi: 10.33667/2078-5631-2022-12-7-11

[59] Fursov AB, Ospanov OB, Fursov RA. Obesity and covid-19 — signs of convergence of two pandemics. Guidelines to fight obesity based on the principles of "ROOTS". Obesity and Metabolism. 2021;18(4):456–464. EDN: MRQNEE doi: 10.14341/omet12745

[60] Фурсов А.Б., Оспанов О.Б., Фурсов Р.А. Ожирение и Covid-19 — признаки конвергенции двух пандемий. Рекомендации по борьбе с ожирением, основанные на принципах "ROOTS" // Ожирение и метаболизм. 2021. Т. 18, № 4. С. 456–464. EDN: MRQNEE doi: 10.14341/omet12745

[61] Larsson SC, Spyrou N, Mantzoros CS. Body fatness associations with cancer: evidence from recent epidemiological studies and future directions. Metabolism. 2022;137:155326. doi: 10.1016/j.metabol.2022.155326

[62] Larsson S.C., Spyrou N., Mantzoros C.S. Body fatness associations with cancer: evidence from recent epidemiological studies and future directions // Metabolism. 2022. Vol. 137. P. 155326. doi: 10.1016/j.metabol.2022.155326

[63] Tikhonov SV, Simanenkov VI, Bakulina NV, et al. Multitarget therapy in patients with GERD and obesity. Medical Alphabet. 2021;(6):8–13. EDN: NTYKCH doi: 10.33667/2078-5631-2021-6-8-13

[64] Тихонов С.В., Симаненков В.И., Бакулина Н.В., и др. Мультитаргетная терапия у пациентов с ГЭРБ и ожирением // Медицинский алфавит. 2021. № 6. С. 8–13. EDN: NTYKCH doi: 10.33667/2078-5631-2021-6-8-13

[65] Akkaliev MN, AukenovNYe, Massabayeva MR, et al. The relationship between types of obesity and testosterone levels in men with age-related hypogonadism from kazakh population. Science & Healthcare. 2021;23(5):125–131.

[66] Akkaliev M.N., Aukenov N.Ye., Massabayeva M.R., et al. The relationship between types of obesity and testosterone levels in men with age-related hypogonadism from kazakh population // Science & Healthcare. 2021. Vol. 23, N 5. P. 125–131.

[67] Purdy JC, Shatzel JJ. The hematologic consequences of obesity. Eur J Haematol. 2021;106(3):306–319. doi: 10.1111/ejh.13560

[68] Purdy J.C., Shatzel J.J. The hematologic consequences of obesity // Eur J Haematol. 2021. Vol. 106, N 3. P. 306–319. doi: 10.1111/ejh.13560

[69] Kim C, Youm S. Development of an obesity information diagnosis model reflecting body type information using 3D body information values. Sensors (Basel). 2022;22(20):7808. doi: 10.3390/s22207808

[70] Kim C., Youm S. Development of an obesity information diagnosis model reflecting body type information using 3D body information values // Sensors (Basel). 2022. Vol. 22, N 20. P. 7808. doi: 10.3390/s22207808

[71] O'Neill D. Measuring obesity in the absence of a gold standard. Econ Hum Biol. 2015;17:116–128. doi: 10.1016/j.ehb.2015.02.002

[72] O'Neill D. Measuring obesity in the absence of a gold standard // Econ Hum Biol. 2015. Vol. 17. P. 116–128. doi: 10.1016/j.ehb.2015.02.002

[73] Gradidge PJ, Norris SA, Crowther NJ. The effect of obesity on the waist circumference cut-point used for the diagnosis of the metabolic syndrome in African women: results from the SWEET study. Int J Environ Res Public Health. 2022;19(16):10250. doi: 10.3390/ijerph191610250

[74] Gradidge P.J., Norris S.A., Crowther N.J. The effect of obesity on the waist circumference cut-point used for the diagnosis of the metabolic syndrome in african women: results from the SWEET study // Int J Environ Res Public Health. 2022. Vol. 19, N 16. P. 10250. doi: 10.3390/ijerph191610250

[75] Dedov II, Shestakova MV, Melnichenko GA, et al. Interdisciplinary clinical practice guidelines "Management of obesity and its comorbidities". Obesity and Metabolism. 2021;18(1):5–99. EDN: AHSBSE doi: 10.14341/omet12714

[76] Дедов И.И., Шестакова М.В., Мельниченко Г.А., и др. Междисциплинарные клинические рекомендации «Лечение ожирения и коморбидных заболеваний» // Ожирение и метаболизм. 2021. Т. 18, № 1. С. 5–99. EDN: AHSBSE doi: 10.14341/omet12714

[77] Bardia A, Holtan SG, Slezak JM, Thompson WG. Diagnosis of obesity by primary care physicians and impact on obesity management. Mayo Clin Proc. 2007;82(8):927–932. doi: 10.4065/82.8.927

[78] Bardia A., Holtan S.G., Slezak J.M., Thompson W.G. Diagnosis of obesity by primary care physicians and impact on obesity management // Mayo Clin Proc. 2007. Vol. 82, N 8. P. 927–932. doi: 10.4065/82.8.927

[79] Pearce C, Rychetnik L, Wutzke S, Wilson A. Obesity prevention and the role of hospital and community-based health services: a scoping review. BMC Health Serv Res. 2019;19(1):453. doi: 10.1186/s12913-019-4262-3

[80] Pearce C., Rychetnik L., Wutzke S., Wilson A. Obesity prevention and the role of hospital and community-based health services: a scoping review // BMC Health Serv Res. 2019. Vol. 19, N 1. P. 453. doi: 10.1186/s12913-019-4262-3

[81] Palacios C, Magnus M, Arrieta A, et al. Obesity in Latin America, a scoping review of public health prevention strategies and an overview of their impact on obesity prevention. Public Health Nutr. 2021;24(15):5142–5155. doi: 10.1017/S1368980021001403

[82] Palacios C., Magnus M., Arrieta A., et al. Obesity in Latin America, a scoping review of public health prevention strategies and an overview of their impact on obesity prevention // Public Health Nutr. 2021. Vol. 24, N 15. P. 5142–5155. doi: 10.1017/S1368980021001403

[83] Shabutdinova OR, Dautov AR, Samkov AA, et al. Semaglutide — effectiveness in weight loss and side effects when used according to studies by SUSTAIN, PIONEER, STEP. Problems of Endocrinology. 2023;69(3):68–82. EDN: MQQLQH doi: 10.14341/probl13197

[84] Шабутдинова О.Р., Даутов А.Р., Самков А.А., и др. Семаглутид — эффективность в снижении веса и побочные эффекты при применении по данным исследований SUSTAIN, PIONEER, STEP // Проблемы эндокринологии. 2023. Т. 69, № 3. С. 68–82. EDN: MQQLQH doi: 10.14341/probl13197

[85] Druzhilov MA, Kuznetsova TYu, Chumakova GA. promising areas of pharmacotherapy for obesity. Russian Journal of Cardiology. 2021;26(3):95–101. EDN: ZPTZXN doi: 10.15829/1560-4071-2021-4279

[86] Дружилов М.А., Кузнецова Т.Ю., Чумакова Г.А. Перспективные направления фармакотерапии ожирения // Российский кардиологический журнал. 2021. Т. 26, № 3. С. 95–101. EDN: ZPTZXN doi: 10.15829/1560-4071-2021-4279

[87] Rippe JM, Hess S. The role of physical activity in the prevention and management of obesity. J Am Diet Assoc. 1998;98(10 Suppl. 2):S31–S38. doi: 10.1016/s0002-8223(98)00708-1

[88] Rippe J.M., Hess S. The role of physical activity in the prevention and management of obesity // J Am Diet Assoc. 1998. Vol. 98, N 10 (Suppl. 2). P. S31–S38. doi: 10.1016/s0002-8223(98)00708-1

[89] Beauchamp A, Backholer K, Magliano D, Peeters A. The effect of obesity prevention interventions according to socioeconomic position: a systematic review. Obes Rev. 2014;15(7):541–554. doi: 10.1111/obr.12161

[90] Beauchamp A., Backholer K., Magliano D., Peeters A. The effect of obesity prevention interventions according to socioeconomic position: a systematic review // Obes Rev. 2014. Vol. 15, N 7. P. 541–554. doi: 10.1111/obr.12161

[91] Dyer RG. Traditional treatment of obesity: does it work? Baillieres Clin Endocrinol Metab. 1994;8(3):661–688. doi: 10.1016/s0950-351x(05)80290-3

[92] Dyer R.G. Traditional treatment of obesity: does it work? // Baillieres Clin Endocrinol Metab. 1994. Vol. 8, N 3. P. 661–688. doi: 10.1016/s0950-351x(05)80290-3

[93] Mironov VI, Khodasevich LS. The use of physical therapeutic factors to prevent obesity and correct overweight. Resort Medicine. 2022;(3):82–94. EDN: VVRYEP doi: 10.51871/2304-0343_2022_3_82

[94] Миронов В.И., Ходасевич Л.С. Использование физических лечебных факторов для профилактики ожирения и коррекции избыточного веса // Курортная медицина. 2022. № 3. С. 82–94. EDN: VVRYEP doi: 10.51871/2304-0343_2022_3_82

[95] Fried M, Yumuk V, Oppert JM, et al. Interdisciplinary European guidelines on metabolic and bariatric surgery. Obes Surg. 2014;24(1):42–55. doi: 10.1007/s11695-013-1079-8

[96] Fried M., Yumuk V., Oppert J.M., et al. Interdisciplinary European guidelines on metabolic and bariatric surgery // Obes Surg. 2014. Vol. 24, N 1. P. 42–55. doi: 10.1007/s11695-013-1079-8

[97] Dedov II, Mel'nichenko GA, Shestakova MV, et al. Russian national clinical recommendations for morbid obesity treatment in adults. 3rd revision (morbid obesity treatment in adults). Obesity and Metabolism. 2018;15(1):53–70. EDN: OUJNNF doi: 10.14341/omet2018153-70

[98] Дедов И.И., Мельниченко Г.А., Шестакова М.В., и др. Национальные клинические рекомендации по лечению морбидного ожирения у взрослых. 3-й пересмотр: Лечение морбидного ожирения у взрослых // Ожирение и метаболизм. 2018. Т. 15, № 1. Р. 53–70. EDN: OUJNNF doi: 10.14341/omet2018153-70

[99] Matveev GA, Golikova TI, Vasileva AA, et al. Comparison of the effects of liraglutide and sibutramine in obese patients. Obesity and Metabolism. 2021;18(2):218–228. EDN: VILJZF doi: 10.14341/omet12498

[100] Матвеев Г.А., Голикова Т.И., Васильева А.А., и др. Сравнение эффектов терапии ожирения лираглутидом и сибутрамином // Ожирение и метаболизм. 2021. Т. 18, № 2. С. 218–228. EDN: VILJZF doi: 10.14341/omet12498

[101] Srivastava G, Apovian C. Future pharmacotherapy for obesity: new anti-obesity drugs on the horizon. Curr Obes Rep. 2018;7(2):147–161. doi: 10.1007/s13679-018-0300-4

[102] Srivastava G., Apovian C. Future pharmacotherapy for obesity: new anti-obesity drugs on the horizon // Curr Obes Rep. 2018. Vol. 7, N 2. P. 147–161. doi: 10.1007/s13679-018-0300-4

[103] Stumbo P, Hemingway D, Haynes WG. Dietary and medical therapy of obesity. Surg Clin North Am. 2005;85(4):703-vi. doi: 10.1016/j.suc.2005.04.002

[104] Stumbo P., Hemingway D., Haynes W.G. Dietary and medical therapy of obesity // Surg Clin North Am. 2005. Vol. 85, N 4. P. 703–723. doi: 10.1016/j.suc.2005.04.002

[105] Garvey WT. Phentermine and topiramate extended-release: a new treatment for obesity and its role in a complications-centric approach to obesity medical management. Expert Opin Drug Saf. 2013;12(5):741–756. doi: 10.1517/14740338.2013.806481

[106] Garvey W.T. Phentermine and topiramate extended-release: a new treatment for obesity and its role in a complications-centric approach to obesity medical management // Expert Opin Drug Saf. 2013. Vol. 12, N 5. P. 741–756. doi: 10.1517/14740338.2013.806481

[107] Boulghassoul-Pietrzykowska N, Franceschelli J, Still C. New medications for obesity management: changing the landscape of obesity treatment. Curr Opin Endocrinol Diabetes Obes. 2013;20(5):407–411. doi: 10.1097/01.med.0000433059.78485.fa

[108] Boulghassoul-Pietrzykowska N., Franceschelli J., Still C. New medications for obesity management: changing the landscape of obesity treatment // Curr Opin Endocrinol Diabetes Obes. 2013. Vol. 20, N 5. P. 407–411. doi: 10.1097/01.med.0000433059.78485.fa

[109] Lebovitz HE. Interventional treatment of obesity and diabetes: An interim report on gastric electrical stimulation. Rev Endocr Metab Disord. 2016;17(1):73–80. doi: 10.1007/s11154-016-9350-7

[110] Lebovitz H.E. Interventional treatment of obesity and diabetes: An interim report on gastric electrical stimulation // Rev Endocr Metab Disord. 2016. Vol. 17, N 1. P. 73–80. doi: 10.1007/s11154-016-9350-7

[111] Kissane NA, Pratt JS. Medical and surgical treatment of obesity. Best Pract Res Clin Anaesthesiol. 2011;25(1):11–25. doi: 10.1016/j.bpa.2011.01.001

[112] Kissane N.A., Pratt J.S. Medical and surgical treatment of obesity // Best Pract Res Clin Anaesthesiol. 2011. Vol. 25, N 1. P. 11–25. doi: 10.1016/j.bpa.2011.01.001

[113] English WJ, DeMaria EJ, Brethauer SA, et al. American Society for Metabolic and Bariatric Surgery estimation of metabolic and bariatric procedures performed in the United States in 2016. Surg Obes Relat Dis. 2018;14(3):259–263. doi: 10.1016/j.soard.2017.12.013

[114] English W.J., DeMaria E.J., Brethauer S.A., et al. American Society for Metabolic and Bariatric Surgery estimation of metabolic and bariatric procedures performed in the United States in 2016 // Surg Obes Relat Dis. 2018. Vol. 14, N 3. P. 259–263. doi: 10.1016/j.soard.2017.12.013

[115] Scopinaro N, Gianetta E, Adami GF, et al. Biliopancreatic diversion for obesity at eighteen years. Surgery. 1996;119(3):261–268. doi: 10.1016/s0039-6060(96)80111-5

[116] Scopinaro N., Gianetta E., Adami G.F., et al. Biliopancreatic diversion for obesity at eighteen years // Surgery. 1996. Vol. 119, N 3. P. 261–268. doi: 10.1016/s0039-6060(96)80111-5

[117] Scopinaro N. The IFSO and obesity surgery throughout the world. International Federation for the Surgery of Obesity. Obes Surg. 1998;8(1):3–8. doi: 10.1381/096089298765554971

[118] Scopinaro N. The IFSO and obesity surgery throughout the world. International Federation for the Surgery of Obesity // Obes Surg. 1998. Vol. 8, N 1. P. 3–8. doi: 10.1381/096089298765554971

[119] Kolle K, Bo O, Stadaas J. Gastric banding. In: OMGI 7th Congress. Stockholm, 1982. P. 37.

[120] Kolle K., Bo O., Stadaas J. Gastric banding. In: OMGI 7th Congress. Stockholm, 1982. P. 37.

[121] Vreeswijk SJ, van Rutte PW, Nienhuijs SW, et al. The safety and efficiency of a fast-track protocol for sleeve gastrectomy: a team approach. Minerva Anestesiol. 2018;84(8):898–906. doi: 10.23736/S0375-9393.17.12298-4

[122] Vreeswijk S.J., van Rutte P.W., Nienhuijs S.W., et al. The safety and efficiency of a fast-track protocol for sleeve gastrectomy: a team approach // Minerva Anestesiol. 2018. Vol. 84, N 8. P. 898–906. doi: 10.23736/S0375-9393.17.12298-4

[123] Bollag RJ, Zhong Q, Ding KH, et al. Glucose-dependent insulinotropic peptide is an integrative hormone with osteotropic effects. Mol Cell Endocrinol. 2001;177(1-2):35–41. doi: 10.1016/s0303-7207(01)00405-1

[124] Bollag R.J., Zhong Q., Ding K.H., et al. Glucose-dependent insulinotropic peptide is an integrative hormone with osteotropic effects // Mol Cell Endocrinol. 2001. Vol. 177(1-2). P. 35–41. doi: 10.1016/s0303-7207(01)00405-1

[125] Yashkov YI. Effectiveness of surgical methods of obesity treatment in type II diabetes mellitus. Surgery. 2000;(12):49–54. (In Russ.)

[126] Яшков Ю.И. Эффективность хирургических методов лечения ожирения при сахарном диабете II типа // Хирургия. 2000. № 12. С. 49–54.

[127] Reid TJ, Korner J. Medical and surgical treatment of obesity. Med Clin North Am. 2022;106(5):837–852. doi: 10.1016/j.mcna.2022.03.002

[128] Reid T.J., Korner J. Medical and surgical treatment of obesity // Med Clin North Am. 2022. Vol. 106, N 5. P. 837–852. doi: 10.1016/j.mcna.2022.03.002

[129] Volkova AR, Fishman MB, Semikova GV. Thyroid-stimulating hormone, leptin and insulin resistance in patients with obesity after bariatric surgery. Obesity and Metabolism. 2020;17(2):187–192. EDN: BGTTTE doi: 10.14341/omet11887

[130] Волкова А.Р., Фишман М.Б., Семикова Г.В. Тиреотропный гормон, лептин и показатели инсулинорезистентности у пациентов с ожирением после бариатрических вмешательств // Ожирение и метаболизм. 2020. Т. 17, № 2. С. 187–192. EDN: BGTTTE doi: 10.14341/omet11887

[131] Askarpour M, Alizadeh S, Hadi A, et al. Effect of bariatric surgery on the circulating level of adiponectin, chemerin, plasminogen activator inhibitor-1, leptin, resistin, and visfatin: a systematic review and meta-analysis. Horm Metab Res. 2020;52(4):207–215. doi: 10.1055/a-1129-6785

[132] Askarpour M., Alizadeh S., Hadi A., et al. Effect of bariatric surgery on the circulating level of adiponectin, chemerin, plasminogen activator inhibitor-1, leptin, resistin, and visfatin: a systematic review and meta-analysis // Horm Metab Res. 2020. Vol. 52, N 4. P. 207–215. doi: 10.1055/a-1129-6785

[133] Mazurina NV, Sviridonova MA. Endocrine and metabolic aspects of the management of patients undergoing bariatric surgery. Review of clinical recommendations. Obesity and Metabolism. 2012;9(1):51–57. EDN: PDQNST

[134] Мазурина Н.В., Свиридонова М.А. Эндокринные и метаболические аспекты ведения пациентов, перенесших бариатрические операции. По материалам клинических рекомендаций Общества эндокринологов // Ожирение и метаболизм. 2012. № 1. С. 51–57. EDN: PDQNST

[135] Yashkov YuI, Lutsevich OE, Nikol'skiy AV, Bekuzarov DK. Comparative evaluation of different operative methods for treating obesity. Obesity and Metabolism. 2008;5(1):31–38. EDN: SZWDGP doi: 10.14341/OMET2008131-38

[136] Яшков Ю.И., Луцевич О.Э., Никольский А.В., Бекузаров Д.К. Сравнительная оценка различных оперативных методов лечения ожирения // Ожирение и метаболизм. 2008. Т. 5, № 1. С. 31–38. EDN: SZWDGP doi: 10.14341/OMET2008131-38

RIGHTS & PERMISSIONS

Eco-Vector